Grosicki, S., Ali, H., Al-Ali, H. K., Ammatuna, E., Bose, P., Urian, L. G., Grudeva-Popova, Z., Gutiérrez, V. G., Hlusi, A., Hou, H., Lee, S., Loschi, M., Sullivan, J. O., Patriarca, A., Rampal, R., Tantravahi, S., Vachhani, P., Chai, Y., Taverna, P., Miljkovic, D., Galleu, A., Potter, V., Mascarenhas, J. (2025). Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics. Blood. https://doi.org/10.1182/blood-2025-7353